Blue Fin Capital’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $645K | Buy |
15,105
+310
| +2% | +$16.8K | 0.09% | 95 |
|
|
2026
Q1 | $928K | Buy |
14,795
+1,696
| +13% | +$136K | 0.15% | 83 |
|
|
2025
Q4 | $1.25M | Sell |
13,099
-547
| -4% | -$53.6K | 0.19% | 70 |
|
|
2025
Q3 | $1.33M | Buy |
13,646
+43
| +0.3% | +$4.45K | 0.21% | 67 |
|
|
2025
Q2 | $1.46M | Buy |
13,603
+44
| +0.3% | +$4.45K | 0.25% | 63 |
|
|
2025
Q1 | $1.37M | Buy |
13,559
+2,596
| +24% | +$261K | 0.27% | 62 |
|
|
2024
Q4 | $979K | Buy |
10,963
+550
| +5% | +$48.4K | 0.18% | 75 |
|
|
2024
Q3 | $873K | Buy |
10,413
+406
| +4% | +$32K | 0.17% | 81 |
|
|
2024
Q2 | $771K | Buy |
10,007
+1,419
| +17% | +$104K | 0.15% | 81 |
|
|
2024
Q1 | $588K | Buy |
8,588
+706
| +9% | +$45.4K | 0.13% | 89 |
|
|
2023
Q4 | $456K | Sell |
7,882
-142
| -2% | -$7.58K | 0.12% | 93 |
|
|
2023
Q3 | $424K | Buy |
8,024
+1,334
| +20% | +$70K | 0.12% | 94 |
|
|
2023
Q2 | $362K | Hold |
6,690
| – | – | 0.1% | 107 |
|
|
2023
Q1 | $347K | Hold |
6,690
| – | – | 0.11% | 105 |
|
|
2022
Q4 | $310K | Hold |
6,690
| – | – | 0.11% | 108 |
|
|
2022
Q3 | $259K | Sell |
6,690
-122
| -2% | -$4.89K | 0.1% | 111 |
|
|
2022
Q2 | $253K | Hold |
6,812
| – | – | 0.09% | 116 |
|
|
2022
Q1 | $301K | Sell |
6,812
-55
| -0.8% | -$2.38K | 0.09% | 113 |
|
|
2021
Q4 | $291K | Sell |
6,867
-171
| -2% | -$7.19K | 0.08% | 116 |
|
|
2021
Q3 | $305K | Sell |
7,038
-316
| -4% | -$14K | 0.09% | 103 |
|
|
2021
Q2 | $314K | Sell |
7,354
-321
| -4% | -$13.5K | 0.1% | 98 |
|
|
2021
Q1 | $296K | Sell |
7,675
-422
| -5% | -$16K | 0.1% | 101 |
|
|
2020
Q4 | $291K | Sell |
8,097
-672
| -8% | -$24.2K | 0.1% | 97 |
|
|
2020
Q3 | $335K | Buy |
8,769
+661
| +8% | +$25.5K | 0.14% | 90 |
|
|
2020
Q2 | $284K | Buy |
8,108
+646
| +9% | +$23.3K | 0.13% | 94 |
|
|
2020
Q1 | $243K | Buy |
7,462
+300
| +4% | +$11.7K | 0.13% | 102 |
|
|
2019
Q4 | $322K | Buy |
7,162
+656
| +10% | +$27.4K | 0.15% | 108 |
|
|
2019
Q3 | $264K | Sell |
6,506
-278
| -4% | -$11.8K | 0.14% | 110 |
|
|
2019
Q2 | $291K | Buy |
6,784
+431
| +7% | +$16.6K | 0.15% | 110 |
|
|
2019
Q1 | $243K | Buy |
+6,353
| New | +$243K | 0.13% | 118 |
|
|
2014
Q2 | – | Sell |
-16,600
| Closed | -$224K | – | 130 |
|
|
2014
Q1 | $224K | Sell |
16,600
-875
| -5% | -$11.5K | 0.2% | 110 |
|
|
2013
Q4 | $210K | Buy |
+17,475
| New | +$206K | 0.19% | 114 |
|
Other funds holding BSX
ATO
RG
Blue Fin Capital's BSX Position: Q2 2026 in Review
Blue Fin Capital increased its Boston Scientific (BSX) stake by 2.1% in Q2 2026, buying an estimated $16.8K and bringing the position to 15,105 shares worth $645K. The position accounts for 0.09% of the portfolio, ranked #95.
Blue Fin Capital first reported a position in BSX in Q4 2013 and has held it in 32 quarters since. The position peaked at $1.46M in Q2 2025. 614 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Blue Fin Capital held 15,105 shares of Boston Scientific worth $645K as of Q2 2026.
- Blue Fin Capital bought 310 Boston Scientific shares in Q2 2026, an estimated $16.8K.
- Boston Scientific made up 0.09% of Blue Fin Capital's portfolio in Q2 2026, its #95 holding.
- Blue Fin Capital first reported a position in Boston Scientific in Q4 2013 and has held it in 32 quarters since.
- Blue Fin Capital's Boston Scientific position peaked at $1.46M in Q2 2025.
- 614 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Blue Fin Capital's 13F filing for Q2 2026, filed 4 Aug 2026.